The Ras-like GTPases RalA and RalB are important drivers of tumour growth and metastasis 1 . Chemicals that block Ral function would be valuable as research tools and for cancer therapeutics. Here we used protein structure analysis and virtual screening to identify drug-like molecules that bind to a site on the GDP-bound form of Ral. The compounds RBC6, RBC8 and RBC10 inhibited the binding of Ral to its effector RALBP1, as well as inhibiting Ral-mediated cell spreading of murine embryonic fibroblasts and anchorage-independent growth of human cancer cell lines. The binding of the RBC8 derivative BQU57 to RalB was confirmed by isothermal titration calorimetry, surface plasmon resonance and 1 H-15 N transverse relaxation-optimized spectroscopy (TROSY) NMR spectroscopy. RBC8 and BQU57 show selectivity for Ral relative to the GTPases Ras and RhoA and inhibit tumour xenograft growth to a similar extent to the depletion of Ral using RNA interference. Our results show the utility of structure-based discovery for the development of therapeutics for Ral-dependent cancers.
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More than one-third of human tumours harbour activating RAS mutations 2 , which has motivated extensive efforts to develop inhibitors of Ras for cancer therapy. However, therapies directed at interfering with post-translational modifications of Ras 3 had poor clinical performance; therefore, efforts shifted to targeting the signalling components downstream of Ras such as the Raf-MEK-ERK mitogen-activated protein kinase pathway 4 and the phosphatidylinositol-3-OH kinase-AKT-mTOR pathway 5 . A third pathway downstream of Ras leads to the activation of the Ras-like small GTPases RalA and RalB 6 , and this pathway has not been targeted to date. Active Ral activates cellular processes through effectors, including Ral-binding protein 1 (RALBP1; also known as RLIP76 and RIP1) 7 , the human exocyst subunits SEC5 and EXO84, filamin and phospholipase D1 (refs 8-10) . These effectors mediate regulation of cell adhesion (anchorage independence), membrane trafficking (exocytosis and endocytosis), mitochondrial fission, and transcription. RalA and RalB are important drivers of the proliferation, survival and metastasis of multiple human cancers, including skin 11 , lung 12 , pancreatic 1 , colon 13 , prostate 14 , and bladder 15, 16 cancers. We set out to discover small molecules that inhibit the intracellular actions of the Ral-family GTPases. Our approach was based on the hypothesis that molecules that selectively bind to Ral-GDP might restrict Ral to an inactive state in the cell, making it unavailable to promote processes linked to tumorigenesis. Comparing the available three-dimensional structures of RalA revealed differences in a region adjacent to, but distinct from, the guanine nucleotide binding pocket (Fig. 1 ). This site is formed by the switch-II region (amino acids 70-77), the a2 helix (amino acids 78-85) and one face of the a3 helix (Fig. 1a) . Its proximity to the previously described C3bot binding site 17 supports the notion that small molecule occupancy at this site could inhibit function. The crystal structures used in the comparison included RalA-GDP (Protein Data Bank (PDB) ID, 2BOV; Fig. 1a, b) and RalA-GNP (RalA bound to a non-hydrolysable form of GTP, the GTP analogue GMP-PNP) in complex with EXO84 (PDB ID, 1ZC4; Fig. 1c) or SEC5 (PDB ID, 1UAD, Fig. 1d ). The volumes calculated for this binding site were 175 Å 3 for RalA-GDP (Fig. 1b) , 155 Å 3 for RalA-GNP-EXO84 (Fig. 1c ) and 116 Å 3 for RalA-GNP-SEC5 (Fig. 1d) . To the best of our knowledge, a RalB-GDP crystal structure is not available. However, in the RalB-GNP structure (PDB ID, 2KE5; Extended Data Fig. 1 ), this binding site is largely absent. Next, we used a structure-based virtual screening approach 18 to identify small molecules that bind to this site in RalA-GDP by individually docking 500,000 compounds to this site (using ChemDiv, v2006.5) 19 and by scoring proteinligand complexes based on calculated interaction energies. This process led to the selection of 88 compounds.
We developed an enzyme-linked immunosorbent assay (ELISA) for assaying Ral activity in living cells based on the selective binding of active RalA-GTP to its effector protein RALBP1. This assay used J82 human bladder cancer cells that stably expressed Flag-tagged RalA. The Flag epitope tag greatly increased the sensitivity and dynamic range of the assay compared with using Ral-specific antibodies for detection (Extended Data Fig. 2a ). Cells were treated with each of the 88 compounds (tested at 50 mM), and then extracts were prepared. The binding of Flag-RalA to recombinant RALBP1 that had been immobilized in 96-well plates was quantified. In this assay, RalA binding reflects Ral's GTP loading and capacity for effector activation. The compounds RBC6, RBC8 and RBC10 (structures shown in Fig. 1e-g ) reduced the activation of RalA in living cells (Fig. 1h) , while compounds RBC5, RBC7 and RBC42 (structures not shown) had no effect and thus served as negative controls. None of the 88 compounds inhibited GTP or GDP binding to purified recombinant RalA (Supplementary Table 1) , which is consistent with the interaction site being distinct from that used for binding guanine nucleotides.
Another cell-based assay was also used to assess the effects of these 88 compounds. Ral is required for lipid raft exocytosis and cell spreading on fibronectin-coated coverslips by murine embryonic fibroblasts (MEFs) 20 . The depletion of RalA with a specific short interfering RNA (siRNA) inhibited the spreading of wild-type MEFs, whereas caveolindeficient (Cav1 2/2 ) MEFs retained the capacity to spread after RalA depletion. When the effects of RBC6, RBC8 and RBC10 on cell spreading in wild-type and Cav1
2/2 MEFs were tested, only the wild-type MEFs were inhibited ( Fig. 1i and Extended Data Fig. 2b ). RBC6 and RBC8 (but not RBC10) are related structures with the same bicyclic core (Fig. 1e-g ); specific substitutions gave rise to similar but somewhat different binding orientations in the allosteric binding cavity (Extended Data Fig. 2c-e) . We therefore focused on RBC6 and RBC8 in further experiments.
To test for the direct binding of compounds to Ral, we used ; therefore, we focused on this isoform. First, we obtained complete backbone NMR chemical shift assignments for the RalB-GDP complex (see Methods), and then we compared the 1 H-15 N-TROSY NMR spectrum of RalB-GDP and RalB-GNP to determine the chemical shift differences between the GTP-bound and GDPbound states. Almost all of the differences were confined to residues that interact with the third phosphate of the GTP (Extended Data Fig. 3a, b) . 1 H-15 N-TROSY spectra were then recorded in the presence of the compound RBC8 or dimethylsulphoxide (DMSO) as a control, and the chemical shift changes were compared. RBC8 induced chemical shift changes in RalB-GDP but not in RalB-GNP, indicating that RBC8 shows selectivity for the GDP-bound form of Ral (Extended Data Fig. 3c, d) . Moreover, RBC5, which did not affect the level of active Ral in the cell-based ELISA assay, did not induce chemical shift changes in RalB-GDP (Extended Data Fig. 3e) , thereby serving as an additional negative control.
On the basis of all of these data, including the structural features, a series of RBC8 derivatives was synthesized and tested for binding in vitro. We chose BQU57 for further evaluation because of its superior performance to RBC8 and its drug-like properties (Fig. 2a, Extended Data Fig. 4a and synthesis pathway in Supplementary Methods). A detailed NMR analysis of the binding between BQU57 and RalB-GDP was carried out. The NMR spectrum of RalB-GDP (100 mM) in the absence and presence of BQU57 (100 mM) is shown in Fig. 2b . Concentration-dependent chemical shift changes for representative residues are shown in Fig. 2c . A plot of the chemical shift changes with BQU57 (100 mM) as a function of sequence (Fig. 2d) shows that residues that exhibit marked changes are located in the switch-II (amino acids 70-77) and a2 helix (amino acids 78-85) regions. Because no RalB-GDP crystal structure is available, a homology model was generated based on similarity to RalA-GDP, and the residues that displayed chemical shift changes in response to the compounds were mapped onto this model (Fig. 2e) . The majority of the chemical shift changes were localized to the allosteric site, consistent with assignment of BQU57 binding to this site based on modelling. Similar to the results for RBC8, BQU57 (100 mM) did not bind to RalB-GNP (100 mM) as indicated by the minimal chemical shift changes in the NMR spectrum (Extended Data Fig. 4b) . Analysis of the NMR chemical shift titrations revealed that the binding of BQU57 was stoichiometric up to the apparent limiting solubility of the drug (which was estimated as ,100 mM in control experiments without protein) (Extended Data Fig. 4c ). The binding of BQU57 to RalB-GDP was also determined, by using isothermal titration calorimetry (ITC), which yielded a dissociation constant (K d ) of 7.7 6 0.6 mM (Fig. 2f) . This finding was similar to the results from surface plasmon resonance (SPR), which gave a K d of 4.7 6 1.5 mM (Extended Data Fig. 4d ).
Next we evaluated the action of RBC8, BQU57 and RBC5 (the last as a negative control) on the human lung cancer cell lines H2122, H358, H460 and Calu-6. Ral promotes anchorage independence 1, 20 ; therefore, we measured cell growth in soft agar. We examined drug uptake and found that RBC8, BQU57 and RBC5 were readily taken into cells (Extended Data Fig. 5a-c) . In addition, we found that all four cell lines were sensitive to siRNA-mediated depletion of K-RAS (Extended Data Fig. 6a, b) but that only H2122 and H358 cells were sensitive to RAL knockdown (Extended Data Fig. 6c, d ). We used this characteristic to assess the specificity of the compounds for inhibiting Ral. Colony formation in soft agar showed that the Ral-dependent lines H2122 and H358, but not H460 or Calu-6, were sensitive to treatment with RBC8 or BQU57 (Fig. 3a, b) . The half-maximum inhibitory concentration (IC 50 ) of RBC8 was 3.5 mM in H2122 cells and 3.4 mM in H358 cells; for BQU57, the IC 50 was 2.0 mM in H2122 cells and 1.3 mM in H358 cells. The inactive control compound RBC5 did not inhibit the growth of any of these cell lines (Extended Data Fig. 5d ). Additionally, a Ral pull-down assay using RALBP1-bound agarose beads 8 showed that RBC8 and BQU57, but not RBC5, inhibited both RalA and RalB activation in both the H2122 and H358 cell lines (Extended Data Fig. 5e ).
To further examine the specificity of these compounds for Ral, RALA and RALB were knocked down in H2122 and H358 cells with specific siRNAs. RBC8 or BQU57 treatment showed no further inhibition of colony formation after RAL knockdown (Fig. 3c-f and Extended Data Fig. 6e ). This supports the conclusion that the inhibition of cell growth All models were generated with Accelrys Discovery Studio software using published structures. c, d, Surface representations of RalA-GNP in complex with EXO84 (EXO84 not shown) (c) and RalA-GNP in complex with SEC5 (SEC5 not shown) (d). e-g, Chemical structure of RBC6 (e), RBC8 (f) and RBC10 (g). h, RalA ELISA results for the top compounds (RBC6, RBC8 and RBC10) and for three ineffective compounds (RBC5, RBC7 and RBC42), as identified by computational screening. J82 cells overexpressing Flag-RalA were treated with each compound for 1 h and then subjected to a RalA ELISA, as described in Methods. Data are presented as the mean 6 s.d. of three technical replicates and expressed as the percentage of DMSO control. i, Dose response effect of RBC6, RBC8 and RBC10 on the RalA-dependent spreading of wildtype MEFs. MEFs were treated with 0-15 mM each compound for 1 h and subjected to the MEF-spreading assay, as described in Methods. Data are presented as the mean 6 s.d. of three technical replicates. 
RESEARCH LETTER

LETTER RESEARCH
by these compounds depends on Ral proteins. Moreover, overexpression of constitutively active (GTP-bound form 22 ) RalA G23V or RalB G23V mutant proteins (Extended Data Fig. 6f ), which do not bind to these compounds (Extended Data Figs 3d and 4b) , mitigated the inhibition of H2122 and H358 cell growth by these compounds (Fig. 3g-j and Extended Data Fig. 6f ). Together, these data provide evidence that RBC8 and BQU57 act specifically through the GDP-bound form of Ral proteins. The inhibition of Ral activity and tumour growth by these compounds were evaluated in human lung cancer xenografts in mice. The pharmacokinetics of RBC8 and BQU57 were analysed in mice. Serum concentrations were determined using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) after intraperitoneal injection of the compound. RBC8 and BQU57 showed properties that define good drug candidates (Extended Data Fig. 7a ). We then determined compound entry to tumour tissue 3 h after dosing, and the compounds were detected in tumour tissue in vivo (Extended Data Fig. 7b, c) . To test the effect of Ral inhibitors on tumour xenograft growth, nude mice were inoculated subcutaneously with H2122 (human) cells and treated intraperitoneally with 50 mg per kg body weight of RBC8 per day for 21 days (except on weekends). RBC8 inhibited tumour growth ( Fig. 4a and Extended Data Fig. 7d ) to a similar extent to dual knockdown of RALA and RALB (Fig. 4b) . Another lung cancer line, H358, yielded similar results (Extended Data  Fig. 7e ). BQU57 was tested in vivo at several different doses (10, 20 and 50 mg per kg body weight per day), and dose-dependent growth inhibition effects were observed (Fig. 4c) .
To further evaluate the specificity of the compounds for the Ral-family GTPases, H2122 tumour xenografts (median size, 250 mm 3 ) were collected 3 h after a single intraperitoneal injection of RBC5 (50 mg per kg body weight), RBC8 (50 mg per kg body weight) or BQU57 (10, 20 and 50 mg per kg body weight), and the activation of Ral in tumour extracts was analysed in RALBP1 pull-down assays. Both RalA and RalB were inhibited by RBC8 (Extended Data Fig. 8a-d ) and by BQU57 (Fig. 4d) but not by the inactive compound RBC5 (Extended Data Fig. 8e, f) . By contrast, no inhibition of Ras or RhoA activity was observed (Fig. 4d) .
One reason for the failures to obtain clinically useful inhibitors of Ras and other related GTPases is the highly conserved guanine nucleotide binding site in these GTPases. This site has a high affinity for the guanine nucleotides GDP and GTP, which are present at millimolar concentrations in cells and would out-compete ligands for this site. Similar considerations have delayed the development of protein kinase inhibitors. Indeed some of the best kinase inhibitors have proved not to be competitive with ATP but to be allosteric inhibitors that lock the conformation of protein kinases, such as MEK, in a closed state 23 . Recently, three studies used a similar fragment-based small molecule screening approach to identify compounds that bind to sites on the K-Ras surface and block its SOS-mediated activation [24] [25] [26] , suggesting that this approach has promise.
Although our initial library screening was based on the RalA structure, the selected compounds also bound to RalB, which is not surprising given the similarity of the amino acid sequences and the predicted structures. Molecular docking could not be performed on RalB-GDP since only the RalB-GNP structure is available. However, NMR experiments with RalB-GDP demonstrated interactions within the allosteric site. Moreover, the selected compounds inhibited the activity of both RalA and RalB in cell culture and in human tumour xenografts. Although RalA and RalB have been proposed to have distinct roles in tumorigenesis and metastasis 1, 8, 12, 13 , genetically engineered mouse models have revealed substantial redundancy for Ral proteins in tumorigenesis 12 . These results support the clinical utility of compounds that inhibit both of these GTPases. Although additional medicinal chemistry optimization 
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is required, these Ral inhibitors represent a first generation of valuable tools for elucidating Ral signalling and for developing novel agents for cancer therapy.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Materials.
The human bladder cancer cell line J82 and the human lung cancer cell lines H2122, H358, H460 and Calu-6 were obtained from the ATCC. All cell lines were fingerprinted by short tandem repeat (STR) profiling and tested for mycoplasma contamination. Antibodies specific for the following proteins were used: RalA (BD Biosciences, #610222), RalB (Millipore, #04-037) and Flag tag (Novagen, #71097). siRNAs directed against human RalA and RalB or both were obtained from Dharmacon using published sequences 8 . Activity assay kits for Ras (#BK008) and RhoA (#BK036) were obtained from Cytoskeleton. All 88 Ral-binding compounds (RBCs) were purchased from ChemDiv. Unless otherwise notified, all chemicals were obtained from Sigma-Aldrich. Computation-based molecular modelling. The crystallographic coordinates of the 2.66 Å human RalA-GDP (PDB ID, 2BOV) 27 , RalA-GNP in complex with EXO84 (PDB ID, 1ZC4) 28 and RalA-GNP in complex with SEC5 (PDB ID, 1UAD) 29 crystal structures were obtained from PDB. AutoDock4 was used for the initial library screening. The ChemDiv library v2006.5 was downloaded from the ZINC database 19 and docked into the identified site on RalA-GDP using rigid docking protocols. This library includes 500,000 compounds, excluding those possessing reactive groups, known ADME toxicity and physicochemical properties that lie outside 'drug-likeness' parameters (by Lipinski's rule of five and Veber's rule of two) at pH 7. Ligand molecules were assigned Gasteiger charges and polar hydrogen atoms by the ligand preparation module provided in AutoDockTools. The Lamarckian genetic algorithm in AutoDock4 was used to evaluate ligand binding energies over the conformational search space. We then ranked compounds based on binding energy and selected top compounds for evaluation. RalA ELISA. J82 cells stably overexpressing Flag-RalA were plated at 800,000 cells per well in 6-well plates and allowed to incubate for 16 h. Cells were treated with 500 ml fresh medium containing test compounds (50 mM) or DMSO control (1.0 h; 37 uC). Cells were then washed with ice-cold PBS and collected into ice-cold lysis buffer (750 ml containing 50 mM Tris, pH 7.5, 200 mM NaCl, 1% IGEPAL CA-630, 10 mM MgCl 2 and protease inhibitors). The lysate was cleared by centrifugation, and the supernatants were then flash-frozen and stored at 280 uC until testing. For the ELISA assay, HisGrab Nickel Coated 96-well plate strips (Pierce, #15142) were washed three times with ELISA buffer (200 ml consisting of 50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Tween 20, and 10 mM MgCl 2 ). RALBP1 (0.5 mg 100 ml
21
) was then added to the wells and incubated with rocking (2.0 h at room temperature). The plates were then washed three times with 200 ml ELISA buffer. The plates were placed on ice, and lysates, or lysis buffer control (100 ml), were added to the wells in quadruplicate. The plates were then incubated overnight with rocking at 4 uC followed by two washes with ice-cold ELISA buffer. Mouse anti-Flag antibody (Sigma, F1804; 1:20,000 in ELISA buffer) was then added at 100 ml per well and incubated (1.0 h, 4 uC). After three washes, goat anti-mouse antibody conjugated to horseradish peroxidase (HRP) (Pierce, #31430; 1:2,500) was added at 100 ml per well and incubated (1.0 h, 4 uC). HRP substrate (Vector Laboratories, #SK-4400) was added to each well at 100 ml after three washes and incubated (1.0 h, room temperature). The reactions were stopped by adding 2 M sulphuric acid (100 ml). Absorbance was read at 450 nm on a BioTek Synergy Hybrid Multi-Mode H1 plate reader (BioTek Instruments). The absorbance was corrected for background absorbance by subtracting the reading for the same well at 540 nm. MEF spreading assay. The MEF spreading assay was performed according to published procedures 20 . Briefly, wild-type or Cav 2/2 MEFs were starved for 24 h, detached from culture plates with Accutase Cell Detachment Solution (Innovative Cell Technologies), resuspended in DMEM with 0.2% serum and 0.5% methyl cellulose, and held in suspension (90 min, 37 uC). While in suspension, cells were treated with inhibitor or DMSO for 1.0 h. After treatment, cells were rinsed once with DMEM containing 0.2% serum, and equal numbers of cells from all treatments were added to 24-well plates that had been coated overnight (4 uC) with 2.0 mg ml 21 human fibronectin. Cells were allowed to spread for 30 min and then fixed with formaldehyde using standard protocols. To allow visualization, cells were labelled with LavaCell (Active Motif) and visualized with a Nikon TE300 fluorescence microscope. Three distinct regions of each well were imaged, and the cell spread area was quantified using ImageJ. NMR spectroscopy. RalB (Q72L mutant) in a pET16b plasmid (Novagen) was a gift from D. Owen. RalB was purified as previously described 21 , with additional steps for loading with GDP or the non-hydrolysable form of GTP (GNP, SigmaAldrich), which were conducted as previously described 30 . Uniform double labelling of proteins with C]glucose. Samples were prepared for NMR spectroscopy in a buffer consisting of 50 mM sodium phosphate, pH 7.6, 100 mM NaCl and 1.0 mM MgCl 2 . All NMR experiments were recorded on an Agilent 900 MHz system at 25 uC.
Resonance assignments for the RalB-GNP complex were obtained from previously published studies deposited in the BMRB (ID, 15230) . Chemical shift assignments of the RalB-GDP complex were obtained independently using HNCACB, CBCA(CO)NH and CCOCNH-TOCSY experiments. All NMR data were processed using NMRPipe 31 and analysed using the CcpNmr analysis program 32 . Assignments were obtained by automated assignment using PINE 33 followed by manual verification. 15 N-TROSY experiments were used to monitor amide shifts from the RalB protein (100 mM) following the addition of compound reconstituted in deuterated DMSO. DMSO concentrations in the final sample were 0.5% or 1%; control samples were made with 0.5% or 1% deuterated DMSO, and all samples containing compounds were compared with their corresponding DMSO control. Normalized chemical shift changes were calculated according to the equation Dd 5 ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi DdH 2 z(0:15DdN) 2 q , where DdH and DdN are the chemical shift changes for the proton and nitrogen frequencies, respectively. ITC and SPR. ITC experiments were carried out using the MicroCal iTC200 system. RalB protein was purified, as described above. Both protein and drug were prepared in a buffer consisting of 50 mM sodium phosphate, pH 7.6, 100 mM NaCl and 1.0 mM MgCl 2 . The final DMSO concentration was adjusted to 1%. RalB-GDP protein (300 mM) was loaded into the syringe and titrated into drug (25 mM) or buffer alone as control. All experiments were carried out at 25 uC. SPR experiments were carried out using the Biacore 3000 system. RalB protein was purified as above. The running buffer contained PBS, pH 7.4, 1.0 mM GDP, 2.0 mM MgCl 2 and 3% DMSO. The regeneration buffer contained PBS, pH 7.4, 1.0 mM GDP and 2.0 mM MgCl 2 . RalB-GDP protein was immobilized onto a CM5 chip; samples of compound BQU57 in running buffer were injected at 30 ml min 21 for 60 s contact time followed by 5.0 min regeneration. Guanine nucleotide binding. His-RalA (100 ng) was incubated with [c- In vitro growth of human cancer cells. Growth inhibition of human lung cancer cells by the compounds was measured under anchorage-independent conditions in soft agar. Cells were seeded into 6-well plates (coated with a base layer made of 2.0 ml of 1% low-melting-point agarose) at 15,000 cells per well in 3.0 ml of 0.4% low-melting-point agarose containing various concentration of drug. Two to four weeks (depending on the cell line) after incubation, the cells were stained with 1.0 mg ml 21 nitroblue tetrazolium, and colonies were counted under a microscope. The IC 50 values were defined as the concentration of drug that resulted in a 50% reduction in colony number compared with the DMSO-treated control. To determine the growth effects induced by siRNA treatment, cells were transfected with 50 nM siRNA directed against RALA, RALB or both (RalA/B) using methods and sequences described previously 8 . After 48 h, cells were subjected to the soft agar colony formation assay, as described above. For the chemo-genetic experiments, siRNA-treated cells were seeded into soft agar in the presence of various concentrations of drug. For the overexpression experiments, H358 cells stably overexpressing Flag, Flag-RalA G23V or Flag-RalB G23V were generated, and cells were subjected to the soft agar colony formation assay in the presence of drug. Attempts to stably overexpress Flag-RalA G23V or Flag-RalB G23V in H2122 cells were unsuccessful, and the rescue experiments with H2122 cells were carried out 48 h after transient transfection with Flag, Flag-RalA G23V or Flag-RalB G23V using the soft agar colony formation assay in the presence of drug. Cellular uptake and pharmacokinetic and pharmacodynamic studies. To quantify how well the compounds enter cells, H2122 human lung cancer cells were seeded at 3 3 10 5 cells per well in 6-well plates and incubated for 16 h. Compounds (10 mM) were individually dosed in triplicate; cells were then collected into 800 ml ice-cold 1:1:1 mixture of acetonitrile, methanol and water at different time points (1, 5, 15, 30 and 60 min). The drug concentrations in the cell lysates were then determined using the LC-MS/MS methods described below. The pharmacokinetics of RBC8 and BQU57 were determined in nude mice following a single intraperitoneal dose (50 mg per kg body weight). Blood samples were collected into EDTA-coated tubes at time intervals from 15 min to 5 h post dose (9 time points) and centrifuged at 1,500g for 15 min to generate plasma samples. Pharmacokinetic parameters, including the area under the curve (AUC), extrapolated initial concentration (C o ) and half-life (T 1/2 ), were estimated using non-compartmental methods. The pharmacodynamics of compounds were determined in tumour-bearing nude mice following a single intraperitoneal dose of 50 mg per kg body weight. Tissue samples were collected 3.0 h after the injection of RBC8 or BQU57. Tissue samples were then homogenized with two weight volumes of phosphate buffer (pH 7.4). High performance liquid chromatography (HPLC)-MS/MS methods were developed to quantify RBC8 and BQU57 in plasma and tissues. Plasma or homogenized tissue samples were extracted with a 1:1:1 mixture of acetonitrile, methanol and water, mixed and centrifuged. The supernatants were transferred into individual wells of a 96-well plate. The 96-well plate was placed into a LEAP auto-sampler (LEAP Technologies) cool stack (6.0 6 0.1 uC)
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and immediately analysed using a Shimadzu HPLC (Shimadzu Scientific Instruments) equipped with a Zorbax Extend-C18 (50 3 4.6 mm, 5 mm particle size) column (Agilent Technologies) and guard column. The mobile phase consisted of buffer A (10 mM ammonium acetate and 0.1% formic acid in water) and buffer B (a 1:1 mixture of acetonitrile and methanol). A SCIEX 4000 system (Applied Biosystems) was used for compound detection. Standard curves were prepared by spiking compounds into control plasma and tissues (for example, liver, brain, kidney, lung, heart and tumour), and these were used to determine the drug concentrations. Tumour growth in mice. All experiments were approved by the University of Colorado Denver Animal Care and Use Committee and were carried out according to approved protocols. Female athymic nude mice (NCr nu/nu; National Cancer Institute) were received at 5 to 6 weeks of age and were allowed to acclimate for 2 weeks in sterile micro isolator cages with constant temperature and humidity. Mice had free access to food and water. Mice were randomized into six per group immediately before use (no blinding was done). H2122 cells in the logarithmic phase of growth were harvested on the day of use. Cells were suspended in unsupplemented RPMI 1640 medium, and 0.1 ml cells (2 3 10 5 cells) was injected subcutaneously at four sites per mouse. For H358 xenografts, cells (5 3 10 6 ) were mixed with Matrigel (20% final concentration), and 0.1 ml cells was inoculated subcutaneously per site. After cell inoculation, mice were monitored daily and weighed twice weekly, and caliper measurements began when the tumours became visible. Tumour volume was calculated with the equation (L 3 W 2 )/2, where L is the longer dimension of the tumour and W is the shorter dimension. Drug treatment started the day after inoculation. Compounds were dissolved in DMSO and injected intraperitoneally each day (except on weekends) at 10, 20 or 50 mg compound per kg body weight. No obvious toxicities were observed in the control (DMSO) or drug-treated animals as assessed by differences in body weight between the control and drugtreated animals taking tumour size into account. Ral activity in tumour xenografts. Nude mice were subcutaneously inoculated with 5 3 10 6 H2122 cells. When the tumours reached an average of 250 mm 3 , mice were randomized into six mice per group (no blinding was done) and were given an intraperitoneal dose of RBC8 or BQU57 at various concentrations. Tumours were then collected 3 h after injection of RBC8 or BQU57. The RalA and RalB activity in the tumour samples were then measured using the RALBP1 pull-down assay kit (Millipore, #14-415), as described previoulsy 8, 15 . The Ras and RhoA activity in the tumour samples were measured using the respective pull-down assay kits (Cytoskeleton, #BK008 and #BK036). All of the activity assays used western blotting as the final readout. For quantification of the immunoblots, the bands on each blot were first normalized to the respective internal control (10 ng recombinant Ral, Ras or RhoA protein in the right-most lane), and the numbers were then compared between different blots, each of which represented one treatment condition. General statistical methods. Unless otherwise noted, the significance of the difference between control and experimental groups was tested using a two-tailed Student's t-test.
